Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LadRx Planning NDA Submission Under 505(b)(2) for Aldoxorubicin and Other Updates
Details : INNO-206 (aldoxorubicin), a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor. It is being evaluated for treatment of soft tissue sarcoma.
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : ImmunityBio
Deal Size : $356.0 million
Deal Type : Termination
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
Details : With the termination, LadRx regains control of INNO-206 (aldoxorubicin), a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor.
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
March 06, 2024
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : ImmunityBio
Deal Size : $356.0 million
Deal Type : Termination
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LadRx Highlights Patent Issued for Its LADR Technology
Details : INNO-206 (aldoxorubicin) is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker and expresses antitumor ef...
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CytRx Corporation
Deal Size : Undisclosed
Deal Type : Merger
Details : Through the merger with Centurion, the next-generation LADR drugs including INNO-206, are now within CytRx and poised for the last steps required for first-in-human studies, an achievement that could be expected to generate significant value for sharehol...
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
September 03, 2022
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CytRx Corporation
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CytRx Partners with Oncology Development Expert to Advance LADR Platform
Details : Aldoxorubicin, a rationally-engineered cytotoxic delivers well-established anti-cancer agent, doxorubicin, into tumor, utilizes an acid-sensitive linker that selectively binds to albumin, which may allow cytotoxic payload to preferentially accumulate in ...
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ImmunityBio continues to study the effectiveness of N-803 and aldoxorubicin in combination with PD-L1 thaNK in Phase 1 / 2 clinical trials to treat triple negative breast cancer and head and neck cancer.
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nogapendekin Alpha Inbakicept,Aldoxorubicin HCl,PD-L1 t-haNK
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2, open-label study will evaluate the comparative efficacy and overall safety of chemotherapy versus standard-of-care chemotherapy, in combination with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in subjects with locally advanced or metastatic...
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Nogapendekin Alpha Inbakicept,Aldoxorubicin HCl,PD-L1 t-haNK
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aldoxorubicin HCl,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : CytRx Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2, study will evaluate the comparative efficacy and safety of standard-of-care chemotherapy versus standard-of-care chemotherapy, in combination with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in subjects with locally advanced or metastatic p...
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Aldoxorubicin HCl,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : CytRx Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aldoxorubicin HCl,Avelumab,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : CytRx Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
CytRx Highlights Preliminary Results of Cohort C of QUILT 88
Details : Enrollment of Cohort C, which includes Aldoxorubicin and patients who have previously failed two lines of standard-of-care therapy, is expected to be completed in the third quarter of 2021 and an early readout of survival data is expected in the first qu...
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 29, 2021
Lead Product(s) : Aldoxorubicin HCl,Avelumab,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : CytRx Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nogapendekin Alpha Inbakicept,Aldoxorubicin HCl,PD-L1 t-haNK
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine
Details : T cell activation can then be enhanced further by infusion of the company’s proprietary, off-the-shelf, natural killer cell platform and its IL-15 superagonist N-803 (Anktiva).
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Inapplicable
July 27, 2021
Lead Product(s) : Nogapendekin Alpha Inbakicept,Aldoxorubicin HCl,PD-L1 t-haNK
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable